ArticleBiomaterials2018
Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.
Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Development of an extended action fostemsavir lipid nanoparticle.Communications biology · 2024Article
- PLGA Nanoparticles as New Drug Delivery Systems in Leishmaniasis Chemotherapy: A Review of Current Practices.Current medicinal chemistry · 2024Review
- The biological functions of europium-containing biomaterials: A systematic review.Materials today. Bio · 2023Review
- Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution.NeuroImmune pharmacology and therapeutics · 2023Article
- CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.EBioMedicine · 2021Article
- Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs.Nanotheranostics · 2021Article
- Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking.Biomaterials · 2020Article
- Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.Theranostics · 2020Article
- Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019Review
- Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice.Nature communications · 2019Article
- The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.Trends in microbiology · 2019Review
- Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery.Pharmaceutics · 2019Review
- Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases.Drug discovery today · 2019Review
- Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.International journal of nanomedicine · 2019Article
- pH-Sensitive Poly(β-amino ester)s Nanocarriers Facilitate the Inhibition of Drug Resistance in Breast Cancer Cells.Nanomaterials (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Antiretroviral therapy (ART) has changed the outcome of human immunodeficiency virus type one (HIV-1) infection from certain death to a life free of disease co-morbidities. However, infected people must remain on life-long daily ART. ART reduces but fails to eliminate the viral reservoir. In order to improve upon current treatment regimens, our laboratory created long acting slow effective release (LASER) ART nanoformulated prodrugs from native medicines. LASER ART enables antiretroviral drugs (ARVs) to better reach target sites of HIV-1 infection while, at the same time, improve ART's half-life and potency. However, novel ARV design has been slowed by prolonged pharmacokinetic testing requirements. To such ends, tri-modal theranostic nanoparticles were created with single-photon emission computed tomography (SPECT/CT), magnetic resonance imaging (MRI) and fluorescence capabilities to predict LASER ART biodistribution. The created theranostic ARV probes were then employed to monitor drug tissue distribution and potency. Intrinsically
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.